Pembrolizumab as First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
J. Clin. Oncol 2020 Jul 30;[EPub Ahead of Print], E Maubec, M Boubaya, P Petrow, M Beylot-Barry, N Basset-Seguin, L Deschamps, JJ Grob, B Dréno, I Scheer-Senyarich, C Bloch-Queyrat, MT Leccia, A Stefan, P Saiag, F Grange, N Meyer, J de Quatrebarbes, M Dinulescu, D Legoupil, L Machet, O Dereure, O Zehou, H Montaudié, E Wierzbicka-Hainaut, Y Le Corre, S Mansard, S Guégan, JP Arnault, S Dalac, F Aubin, C Alloux, I Lopez, S Cherbal, A Tibi, V LévyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.